激素抵抗性前列腺癌的治疗进展

doi:10.3760/cma.j.issn.1673-422X.2014.01.018

摘要/Abstract

摘要： 多西他赛联合泼尼松的3周治疗方案是激素抵抗性前列腺癌的首选一线化疗方案。近年来许多临床研究着重于研究抗肿瘤血管生成联合多西他赛为基础的治疗方案能否进一步提高疗效、新一代抗雄激素治疗以及多西他赛化疗失败后的解救治疗。对于激素抵抗性前列腺癌，阿比特龙可为首选，Enzalutamide可作为多西他赛耐受后的另一内分泌治疗选择，而化疗联合靶向药物仍然无法挑战多西他赛联合泼尼松的一线治疗地位。

关键词: 前列腺肿瘤, 药物疗法, 抗药性, 肿瘤, 雄激素拮抗药

Abstract: Treatment with docetaxel and prednisone every 3 weeks is preferred in hormone refractory prostate cancer. In recent years, a number of clinical trials are held to assess the efficacy of docetaxelbased regimens combined with antiangiogenesis agents, firstline treatment of androgen ablation, and salvage therapy after chemotherapy failure with docetaxel. For hormone refractory prostate cancer, abiraterone can be used as the first choice, while, enzalutamide can be used as another endocrine therapy for patients who tolerate with docetaxel. However, chemotherapy combined with targeted drugs still cannot challenge the firstline treatment status of docetaxel plus prednisone.

Key words: Prostatic neoplasms, Drug therapy, Drug resistance, neoplasm, Androgen antagonists

王盈, 李绪渊, 林英城. 激素抵抗性前列腺癌的治疗进展[J]. 国际肿瘤学杂志, 2014, 41(1): 56-59.

Wang Ying, Li Xuyuan, Lin Yingcheng. Advance of treatment in hormone refractory prostate cancer[J]. Journal of International Oncology, 2014, 41(1): 56-59.

参考文献

［1］ Seruga B, Tannock IF. Chemotherapybased treatment for castrationresistant prostate cancer［J］. J Clin Oncol, 2011, 29(27):36863694. ［2］ Kelly WK, Halabi S, Carducci M, et al. Randomized, doubleblind, placebocontrolled phase Ⅲ trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castrationresistant prostate cancer: CALGB 90401［J］. J Clin Oncol, 2012, 30(13):15341540. ［3］ Tannock IF, Fizazi K, Ivanov S, et al. Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castrationresistant prostate cancer (VENICE): a phase 3, doubleblind randomised trial［J］. Lancet Oncol, 2013, 14(8):760768. ［4］ Heidenreich A, Rawal SK, Szkarlat K, et al. A randomized, doubleblind, multicenter, phase 2 study of a human monoclonal antibody to human αν integrins (intetumumab) in combination with docetaxel and prednisone for the firstline treatment of patients with metastatic castrationresistant prostate cancer［J］. Ann Oncol, 2013, 24(2):329336. ［5］ Sonpavde G, Matveev V, Burke JM, et al. Randomized phase Ⅱ trial of docetaxel plus prednisone in combination with placebo or AT101, an oral small molecule Bcl2 family antagonist, as firstline therapy for metastatic castrationresistant prostate cancer［J］. Ann Oncol, 2012, 23(7):18031808. ［6］ Chi KN, Hotte SJ, Yu EY, et al. Randomized phase Ⅱ study of docetaxel and prednisone with or without OGX011 in patients with metastatic castrationresistant prostate cancer［J］. J Clin Oncol, 2010, 28(27):42474254. ［7］ Scher HI, Jia X, Chi K, et al. Randomized, openlabel phase Ⅲ trial of docetaxel plus highdose calcitriol versus docetaxel plus prednisone for patients with castrationresistant prostate cancer［J］. J Clin Oncol, 2011, 29(16):21912198. ［8］ Fizazi KS, Higano CS, Nelson JB, et al. Phase Ⅲ, randomized, placebocontrolled study of docetaxel in combination with zibotentan in patients with metastatic castrationresistant prostate cancer［J］. J Clin Oncol, 2013, 31(14):17401747. ［9］ Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy［J］. N Engl J Med, 2013, 368(2):138148. ［10］ Kantoff PW, Higano CS, Shore ND, et al. SipuleucelT immunotherapy for castrationresistant prostate cancer［J］. N Engl J Med, 2010, 363(5):411422. ［11］ Kantoff PW, Schuetz TJ, Blumenstein BA, et al. Overall survival analysis of a phase Ⅱ randomized controlled trial of a Poxviralbased PSAtargeted immunotherapy in metastatic castrationresistant prostate cancer［J］. J Clin Oncol, 2010, 28(7):10991105. ［12］ Fizazi K, Scher HI, Molina A, et al. Abiraterone acetate for treatment of metastatic castrationresistant prostate cancer: final overall survival analysis of the COUAA301 randomised, doubleblind, placebocontrolled phase 3 study［J］. Lancet Oncol, 2012, 13(10):983992. ［13］ Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy［J］. N Engl J Med, 2012, 367(13):11871197. ［14］ de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castrationresistant prostate cancer progressing after docetaxel treatment: a randomised openlabel trial［J］. Lancet, 2010, 376(9747):11471154. ［15］ Fleming MT, Sonpavde G, Kolodziej M, et al. Association of rash with outcomes in a randomized phase Ⅱ trial evaluating cetuximab in combination with mitoxantrone plus prednisone after docetaxel for metastatic castrationresistant prostate cancer［J］. Clin Genitourin Cancer, 2012, 10(1):614. ［16］ Fizazi K, De Bono JS, Flechon A, et al. Randomised phase Ⅱ study of siltuximab (CNTO 328), an antiIL6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castrationresistant prostate cancer［J］. Eur J Cancer, 2012, 48(1):8593. ［17］ Ryan CJ, Rosenthal M, Ng S, et al. Targeted MET inhibition in castrationresistant prostate cancer: a randomized phase Ⅱ study and biomarker analysis with rilotumumab plus mitoxantrone and prednisone［J］. Clin Cancer Res, 2013, 19(1):215224. ［18］ Nakabayashi M, Werner L, Courtney KD, et al. Phase Ⅱ trial of RAD001 and bicalutamide for castrationresistant prostate cancer［J］. BJU Int, 2012, 110(11):17291735. ［19］ Beardsley EK, Hotte SJ, North S, et al. A phase Ⅱ study of sorafenib in combination with bicalutamide in patients with chemotherapynaive castration resistant prostate cancer［J］. Invest New Drugs, 2012, 30(4):16521659. ［20］ Vogelzang NJ, Helle SI, Johannessen DC, et al. Efficacy and safety of radium233 dichloride (Ra233) in castrationresistant prostate cancer (CRPC) patients with bone metastases who did or did not receive prior docetaxel (D) in the phase Ⅲ ALSYMPCA trial［J］. J Clin Oncol, 2013, 31 Suppl 15:S5068.

[1]	刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲. 血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325.
[2]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊. 局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[3]	袁健, 黄燕华. Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[4]	陈红健, 张素青. 血清miR-24-3p、H2AFX与肝癌患者临床病理特征及术后复发的关系研究[J]. 国际肿瘤学杂志, 2024, 51(6): 344-349.
[5]	郭泽浩, 张俊旺. PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[6]	张百红, 岳红云. 新作用机制的抗肿瘤药物进展[J]. 国际肿瘤学杂志, 2024, 51(6): 354-358.
[7]	许凤琳, 吴刚. EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[8]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[9]	张蕊, 褚衍六. 基于FIT与肠道菌群的结直肠癌风险评估模型的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 370-375.
[10]	高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[11]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东. ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[12]	刘静, 刘芹, 黄梅. 基于SMOTE算法的食管癌放化疗患者肺部感染的预后模型构建[J]. 国际肿瘤学杂志, 2024, 51(5): 267-273.
[13]	杨琳, 路宁, 温华, 张明鑫, 朱琳. 炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[14]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝. 癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[15]	张宁宁, 杨哲, 檀丽梅, 李振宁, 王迪, 魏永志. 宫颈细胞DNA倍体分析联合B7-H4和PKCδ对宫颈癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(5): 286-291.